產(chǎn)品名稱(chēng)

MK 2206

產(chǎn)品貨號(hào)

Axon 1684 CAS [1032350-13-2] MF C25H21N5O.2HClMW 480.39 Purity: 99% Soluble in water and DMSO Description An orally potent and highly selective non-ATP-competitive allosteric Akt inhibitor that has nanomolar IC50 values and broad preclinical anti-tumor activities. KEYWORDS: MK 2206 | Akt inhibitor | MK2206 | MK-2206 | CAS [1032350-13-2] | [1032349-93-1] | Axon Medchem | Axon 1684 | Phosphatidylinositol | Akt | Inhibitor | Enzymes

產(chǎn)品價(jià)格

現(xiàn)貨詢(xún)價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

MK 2206

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 1684

CAS [1032350-13-2]

MF C25H21N5O.2HCl
MW 480.39

Purity: 99%
Soluble in water and DMSO

MK 2206

Description

An orally potent and highly selective non-ATP-competitive allosteric Akt inhibitor that has nanomolar IC50 values and broad preclinical anti-tumor activities.

KEYWORDS: MK 2206 | Akt inhibitor | MK2206 | MK-2206 | CAS [1032350-13-2] | [1032349-93-1] | Axon Medchem | Axon 1684 | Phosphatidylinositol | Akt | Inhibitor | Enzymes

H Hirai et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Mol. Cancer Ther. 2010, 9(7), 1956-1967.

AW Tolcher et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. 27:15s, 2009 (suppl; abstr 3503).

R Liu et al. The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway. J. Clin. Endocrinol. Metab. 2011, 96(4), E577-E585.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Akt PI3K-Akt-mTOR EC 2.7.11.1

Akt inhibitor (allosteric)

Chemical name

8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride

Parent CAS No.

[1032349-93-1]

產(chǎn)品資料